Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
European Journal of Haematology|June 24, 2022
Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: A retro-prospective observational studyMaria Livia Del Giudice, Alessandro Gozzetti, Elisabetta Antonioli, et al.Medicina (Kaunas, Lithuania)|September 28, 2021
Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective StudyMaria Livia Del Giudice, Alessandro Gozzetti, Elisabetta Antonioli, et al.Cancers|August 14, 2025
Combined Minimal Residual Disease Evaluation in Bone Marrow and Apheresis Samples in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation Improves Outcome PredictionIrene Attucci, Benedetta Peruzzi, Chiara Nozzoli, et al.Journal of Personalized Medicine|March 25, 2022
Daratumumab in AL Amyloidosis: A Real-Life Experience of the "RTM" (Regional Tuscan Myeloma Network)Vincenzo Sammartano, Elisabetta Antonioli, Gabriele Buda, et al.Frontiers in Oncology|May 14, 2023
Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma NetworkElisabetta Antonioli, Sofia Pilerci, Irene Attucci, et al.British Journal of Haematology|March 26, 2026
MRD-negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥VGPR/MRD-positive after first-line therapy: Final analysis of the open-label, single-arm multicentric phase 2 trial DART4MMAlessandro Gozzetti, Paola Pacelli, Federico Caroni, et al.Haematologica|March 26, 2026
Pomalidomide, bortezomib and dexamethasone in multiple myeloma refractory to lenalidomide and anti-CD38 monoclonal antibodies: outcomes from a real-world experienceCarmine Liberatore, Virginia Valeria Ferretti, Paola Tacchetti, et al.Annals of Hematology|October 7, 2025
Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) ItalyConcetta Conticello, Vittorio Del Fabro, Alessandra Romano, et al.Pageof 1